Therefore, laboratory validation both in vivo and in vitro is envisioned to illuminate the detailed molecular mechanism, and prospective clinical validation with studies involving larger cohorts of breast cancer patients is required to confirm the prognostic value of serum MIF levels. This evidence concerns the gene MIF and breast cancer.